Novo Nordisk stock steadies as Wegovy pill drives guidance tweak and court win
Published on 08/14/2026 at 07:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk A/S (ISIN DK0062498333) stock is consolidating below recent peaks as of August 14, 2026, with investors weighing solid second quarter Wegovy pill sales against a modest guidance cut and mounting GLP-1 competition.
Per recent market data as of August 13, 2026, Novo Nordisk's New York-listed shares closed at $46.75, up 0.78% on the day, while the Danish B-share finished at DKK 298.25, down 0.42%, underscoring a mixed short-term reaction across venues.
At the fundamental level, the company reported second quarter 2026 sales of $12.21 billion (DKK 78.5 billion) at constant exchange rates, a 3% increase versus the prior-year quarter, with oral Wegovy contributing around $500 million (DKK 3.22 billion) and prescriptions for the pill reaching 2.9 million in the period.
Guidance tweak and GLP-1 pill momentum
Recent coverage of Novo Nordisk's second quarter 2026 results highlights that management raised its 2026 guidance to reflect stronger than expected GLP-1 sales, even as oral Wegovy uptake came in below some earlier expectations. One detailed Q2 2026 earnings analysis notes that adjusted sales and operating profit are now expected to decline 0% to 6% at constant exchange rates for 2026, compared with previous guidance calling for a 4% to 12% decline, signaling a measurable improvement in the outlook.
Within that revised framework, the oral Wegovy pill generated $500 million in second quarter 2026 sales and 2.9 million prescriptions, underlining strong absolute demand for the convenience of a pill even if the ramp has been more gradual than the initial injection launch. An oral GLP-1 competition comparison contrasts this performance with rival oral products that recorded lower second quarter revenues, reinforcing Novo Nordisk's lead in the pill segment.
The guidance change amounts to narrowing the expected full-year 2026 decline in adjusted sales and operating profit by 4 percentage points at both the upper and lower ends of the range. That quantified adjustment helps support the share price by signaling that the company now sees less downside risk than previously communicated, thanks in large part to GLP-1 demand for both injections and the new pill.
Court ruling and valuation context
A fresh legal catalyst also underpins Novo Nordisk's semaglutide franchise. A European legal news summary reports that a Dutch court granted Novo Nordisk an injunction in a semaglutide patent case, finding that a generic company had infringed the firm's supplementary protection certificate covering semaglutide. This ruling strengthens the patent shield around key GLP-1 molecules, potentially delaying generic erosion and supporting medium-term pricing power.
On the market side, Novo Nordisk's American depositary shares have shown some volatility around these developments. A valuation-focused commentary notes that the stock traded at $45.93 in recent days, a level that sits 57.74% below one fair value estimate of $108.68, suggesting material upside from a valuation perspective if earnings and cash flows track management's improved guidance.
Despite that apparent discount, year to date Novo Nordisk shares have declined 8.8% compared with an industry gain of 12.6%, indicating that investors remain cautious as the obesity race intensifies and as oral competitors ramp their own products. The same Q2 2026-focused analysis cites a forward price to earnings ratio of 13.85 for Novo Nordisk against 18.73 for the broader peer group, and well below the company's five-year mean of 29.18, reinforcing the picture of a stock that now trades at a lower multiple than its recent history and industry averages.
Consensus and earnings trajectory
Analyst expectations help frame where Novo Nordisk's results may go next. Recent consensus data show that second quarter 2026 performance and GLP-1 trends have left near-term earnings projections mostly intact. For 2026, earnings estimates have stayed at $3.39 per share in the past week, while 2027 estimates have been nudged up from $3.28 to $3.31 per share, implying modest earnings growth beyond 2026 as GLP-1 pills and injectables drive the top line.
A separate view on the broader GLP-1 pill landscape highlights that rival oral products booked $98 million in second quarter 2026 sales, considerably below Novo Nordisk's $500 million Wegovy pill figure. That comparison underscores both the strength of Novo Nordisk's brand and the scale of its launch, even if volumes and revenues will need to accelerate again in the second half to meet management's refined expectations.
The company is also portrayed as trading at a discount to the industry when measured on forward earnings, again pointing to a valuation case that combines lower multiples with a multi-year growth runway in obesity and diabetes. Taken together, the modest 3% year over year increase in second quarter 2026 sales, the narrowed guidance range, and consensus earnings tweaks suggest a business that is stabilizing after an exceptionally strong growth phase rather than one that is stalling outright.
Wegovy pill anchors obesity product strategy
At the product level, Wegovy remains the centerpiece of Novo Nordisk's obesity strategy, now increasingly in oral pill form alongside its established injection. The company distributed 2.9 million Wegovy pill prescriptions in the second quarter of 2026, indicating rapid adoption by patients and prescribers who see value in a non-injectable option for weight management.
The $500 million in second quarter 2026 Wegovy pill sales show that the product already contributes meaningfully to Novo Nordisk's revenue base, and the firm has spoken of ambitions for pill formulations to account for up to a third of GLP-1 use by 2030. While injections continue to dominate volumes today, the pill expansion diversifies delivery modes and potentially broadens the addressable market to those reluctant to use needles.
Future innovation in semaglutide and related molecules, reinforced by the recent Dutch patent decision, may enable higher dose pills, faster onset of weight loss, or combinations with other mechanisms, all of which could deepen Novo Nordisk's competitive moat. For now, the second quarter 2026 figures offer a concrete snapshot of how quickly the Wegovy pill has moved from regulatory approval in late 2025 to substantial revenue within a few quarters.
Novo Nordisk stock price context
From a trading perspective, Novo Nordisk stock currently reflects both strong fundamentals and investor caution. As of the August 13, 2026 close, the New York-listed shares finished at $46.75, with extended trading later that day showing a slight pullback to $46.58, and earlier data citing a recent close at $47.22 alongside a market capitalization of $210.82 billion and daily volume of 7.83 million shares.
In Copenhagen, the B-share closed at DKK 298.25 on August 13, 2026, down DKK 1.25 or 0.42% versus the prior close at DKK 299.50, reflecting a small consolidation after prior gains. A European trading venue quote shows the stock at EUR 40.54 on Tradegate as of August 13, 2026, up 0.70% over the past five days and 4.52% year to date, suggesting a more constructive picture in that cross listing.
For US retail investors, the combination of a 3% year over year rise in second quarter 2026 sales, $500 million in Wegovy pill revenue with 2.9 million prescriptions, a narrowed 0% to 6% expected decline in 2026 adjusted sales and operating profit, and a forward price to earnings ratio of 13.85 versus 18.73 for the industry presents a tangible case that Novo Nordisk stock now embeds more conservative expectations than in the peak of the obesity trade, even as the GLP-1 franchise continues to grow.
Go deeper
Further analysis of Novo Nordisk stock performance and valuation can be found through detailed earnings breakdowns and GLP-1 market comparisons that discuss second quarter 2026 results, guidance changes, and obesity pill adoption trends.
Read more
More on Novo Nordisk stock
Investor Relations
Fact box
Company: Novo Nordisk A/S
ISIN: DK0062498333
Ticker: NVO
Exchange: NYSE and Nasdaq Copenhagen
Price (as of August 13, 2026, 3:59 p.m. ET): $46.75 USD
Market cap: $210.82 billion (as of August 13, 2026)
Sector / Industry: Health care / Pharmaceuticals
Index membership: S&P 500
